The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
Durvet is a safe and effective treatment option for respiratory infections in pets. It is easy to administer, affordable, and well-tolerated by most animals. By understanding the benefits, dosage, and ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...